Announcement • May 28

Imugene Limited Announces Appointment of Charmaine Gittleson and Michael Kotsanis as Non-Executive Directors, Effective June 30, 2026

Imugene Limited announced the appointment of Dr Charmaine Gittleson and Mr. Michael Kotsanis as Non-Executive Directors, effective June 30, 2026. Dr Charmaine Gittleson is a seasoned pharmaceutical physician and biopharmaceutical senior executive with over 20 years of global experience in drug development, clinical strategy, and regulatory affairs. She served as Chief Medical Officer at CSL Limited, where she led global clinical and medical governance across a diverse portfolio of therapies, including rare diseases, immunology, and vaccines. Since transitioning from executive leadership, Dr Gittleson has held Non-Executive roles within a number of ASX-listed life sciences companies, mainly focused on oncology. She is currently Chair of Percheron Therapeutics and is a Non-Executive Director of PolyNovo and George Medicines. She was previously on the Board of Patrys, providing strategic oversight on clinical development, regulatory strategy, and commercial growth. Mr. Michael Kotsanis brings 35 years operational leadership experience in global pharmaceutical markets, leading regional franchises at Hospira/Mayne Pharma and Synthon, driving commercialisation, licensing and market expansion. He returned to Australia in 2014 to assume the CEO position at Acrux, directing pipeline development, business development, capital management/investor relations, and ASX/ASIC compliance for a topical pharmaceutical product developer. Throughout his career he has held numerous Executive Director appointments on the main Board of Synthon and various operating subsidiaries of the listed companies. Mr. Kotsanis is a Non-Executive Director at ICE Pharma, a private equity owned, Italian specialty pharmaceutical company that manufactures active pharmaceutical ingredients. He was formerly a Non-Executive Director at IDT Australia where he was also Chair of the Human Capital/Remuneration Committee and an Audit/Risk Committee member. Post restructuring, the Board will be comprised of Australian biotech leaders, medical oncologists, as well as experienced US biotech executives with NASDAQ experience. The newly constituted Board is currently considering the Board sub-committee composition in accordance with the ASX Corporate Governance Principles and Recommendations, and will provide details in due course.

Imugene Limited Stock Price

IMU Share Price Performance

IMU Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Imugene Limited Key Details

About IMU

Recent IMU News & Updates

Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 11.1245 million.

Imugene Limited has filed a Follow-on Equity Offering in the amount of AUD 11.1245 million.

Imugene Limited Announces Appointment of Charmaine Gittleson and Michael Kotsanis as Non-Executive Directors, Effective June 30, 2026

Recent updates

Imugene Limited Competitors

Vita Life Sciences

Alterity Therapeutics

Island Pharmaceuticals

Nyrada